1026 related articles for article (PubMed ID: 26965997)
1. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways.
Karagoz K; Sinha R; Arga KY
OMICS; 2015 Feb; 19(2):115-30. PubMed ID: 25611337
[TBL] [Abstract][Full Text] [Related]
3. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
4. Preface on application of omics technologies in cancer biology and therapy.
Georgakilas AG
Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
[No Abstract] [Full Text] [Related]
5. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
6. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
[TBL] [Abstract][Full Text] [Related]
7. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
8. Omics-Based Investigations of Breast Cancer.
Neagu AN; Whitham D; Bruno P; Morrissiey H; Darie CA; Darie CC
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375323
[TBL] [Abstract][Full Text] [Related]
9. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Asleh K; Riaz N; Nielsen TO
J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786
[TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
12. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
15. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine.
Golubnitschaja O; Filep N; Yeghiazaryan K; Blom HJ; Hofmann-Apitius M; Kuhn W
Amino Acids; 2018 Apr; 50(3-4):383-395. PubMed ID: 29249020
[TBL] [Abstract][Full Text] [Related]
16. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
[TBL] [Abstract][Full Text] [Related]
17. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
De Palma FDE; Del Monaco V; Pol JG; Kremer M; D'Argenio V; Stoll G; Montanaro D; Uszczyńska-Ratajczak B; Klein CC; Vlasova A; Botti G; D'Aiuto M; Baldi A; Guigó R; Kroemer G; Maiuri MC; Salvatore F
Pharmacol Res; 2020 Nov; 161():105249. PubMed ID: 33068730
[TBL] [Abstract][Full Text] [Related]
18. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Triple-Negative Breast Cancer.
Derakhshan F; Reis-Filho JS
Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
[TBL] [Abstract][Full Text] [Related]
20. Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
Guo J; Gong G; Zhang B
Oncol Rep; 2017 Oct; 38(4):2219-2228. PubMed ID: 28849078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
